Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Metabolism of a 5HT6 Antagonist, 2-Methyl-1-(Phenylsulfonyl)-4-(Piperazin-1-yl)-1H-Benzo[d]imidazole (SAM-760): Impact of Sulfonamide Metabolism on Diminution of a Ketoconazole-Mediated Clinical Drug-Drug Interaction.

Sawant-Basak A, Obach RS, Doran A, Lockwood P, Schildknegt K, Gao H, Mancuso J, Tse S, Comery TA.

Drug Metab Dispos. 2018 Jul;46(7):934-942. doi: 10.1124/dmd.118.080457. Epub 2018 Apr 25.

PMID:
29695615
2.

Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.

Liu J, Ogden A, Comery TA, Spiros A, Roberts P, Geerts H.

CPT Pharmacometrics Syst Pharmacol. 2014 Apr 23;3:e111. doi: 10.1038/psp.2014.7.

3.

Design and synthesis of a hybrid series of potent and selective agonists of α7 nicotinic acetylcholine receptor.

Nencini A, Castaldo C, Comery TA, Dunlop J, Genesio E, Ghiron C, Haydar S, Maccari L, Micco I, Turlizzi E, Zanaletti R, Zhang J.

Eur J Med Chem. 2014 May 6;78:401-18. doi: 10.1016/j.ejmech.2014.03.031. Epub 2014 Mar 19.

PMID:
24704613
4.

Coalition Against Major Diseases: Precompetitive Collaborations and Regulatory Paths to Accelerating Drug Development for Neurodegenerative Diseases.

Stephenson D, Aviles E, Bain LJ, Brumfield M, Carrillo M, Comery TA, Compton C, Corrigan B, Gordon MF, Jack CR Jr, Katz R, Logovinsky V, Satlin A, Marek K, Nicholas T, Polhamus D, Angersbach BS, Raghavan N, Romano G, Romero K, Shaw L, Woodcock J, Vradenburg G, Isaac M.

Ther Innov Regul Sci. 2013 Nov;47(6):632-638. doi: 10.1177/2168479013498386.

PMID:
30235546
5.

N-[5-(5-fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): a medicinal chemistry effort toward an α7 nicotinic acetylcholine receptor agonist preclinical candidate.

Zanaletti R, Bettinetti L, Castaldo C, Ceccarelli I, Cocconcelli G, Comery TA, Dunlop J, Genesio E, Ghiron C, Haydar SN, Jow F, Maccari L, Micco I, Nencini A, Pratelli C, Scali C, Turlizzi E, Valacchi M.

J Med Chem. 2012 Nov 26;55(22):10277-81. doi: 10.1021/jm3013568. Epub 2012 Nov 2.

PMID:
23083093
6.

5-HT(2C) agonists as therapeutics for the treatment of schizophrenia.

Rosenzweig-Lipson S, Comery TA, Marquis KL, Gross J, Dunlop J.

Handb Exp Pharmacol. 2012;(213):147-65. doi: 10.1007/978-3-642-25758-2_6. Review.

PMID:
23027415
7.

Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).

Zanaletti R, Bettinetti L, Castaldo C, Cocconcelli G, Comery T, Dunlop J, Gaviraghi G, Ghiron C, Haydar SN, Jow F, Maccari L, Micco I, Nencini A, Scali C, Turlizzi E, Valacchi M.

J Med Chem. 2012 May 24;55(10):4806-23. doi: 10.1021/jm300247y. Epub 2012 May 3.

PMID:
22468936
8.

Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.

Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG.

J Neurosci. 2012 Feb 22;32(8):2696-702. doi: 10.1523/JNEUROSCI.1676-11.2012.

9.

2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.

Zhou D, Gross JL, Adedoyin AB, Aschmies SB, Brennan J, Bowlby M, Di L, Kubek K, Platt BJ, Wang Z, Zhang G, Brandon N, Comery TA, Robichaud AJ.

J Med Chem. 2012 Mar 8;55(5):2452-68. doi: 10.1021/jm300011d. Epub 2012 Feb 28.

PMID:
22313242
10.

Pyrrolidin-3-yl-N-methylbenzamides as potent histamine 3 receptor antagonists.

Zhou D, Gross JL, Sze JY, Adedoyin AB, Bowlby M, Di L, Platt BJ, Zhang G, Brandon N, Comery TA, Robichaud AJ.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5957-60. doi: 10.1016/j.bmcl.2011.07.061. Epub 2011 Jul 27.

PMID:
21843941
11.

Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.

Marquis KL, Comery TA, Jow F, Navarra RL, Grauer SM, Pulicicchio C, Kelley C, Brennan JA, Roncarati R, Scali C, Haydar S, Ghiron C, Terstappen GC, Dunlop J.

Psychopharmacology (Berl). 2011 Dec;218(4):635-47. doi: 10.1007/s00213-011-2357-6. Epub 2011 Jun 4.

PMID:
21643676
12.

Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT(6) antagonists.

Liu KG, Robichaud AJ, Greenfield AA, Lo JR, Grosanu C, Mattes JF, Cai Y, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE, Comery TA.

Bioorg Med Chem. 2011 Jan 1;19(1):650-62. doi: 10.1016/j.bmc.2010.10.033. Epub 2010 Oct 20.

PMID:
21093272
13.

5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists.

Liu KG, Robichaud AJ, Bernotas RC, Yan Y, Lo JR, Zhang MY, Hughes ZA, Huselton C, Zhang GM, Zhang JY, Kowal DM, Smith DL, Schechter LE, Comery TA.

J Med Chem. 2010 Nov 11;53(21):7639-46. doi: 10.1021/jm1007825.

PMID:
20932009
14.

Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).

Ghiron C, Haydar SN, Aschmies S, Bothmann H, Castaldo C, Cocconcelli G, Comery TA, Di L, Dunlop J, Lock T, Kramer A, Kowal D, Jow F, Grauer S, Harrison B, La Rosa S, Maccari L, Marquis KL, Micco I, Nencini A, Quinn J, Robichaud AJ, Roncarati R, Scali C, Terstappen GC, Turlizzi E, Valacchi M, Varrone M, Zanaletti R, Zanelli U.

J Med Chem. 2010 Jun 10;53(11):4379-89. doi: 10.1021/jm901692q.

PMID:
20465311
15.

The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists.

Childers WE Jr, Havran LM, Asselin M, Bicksler JJ, Chong DC, Grosu GT, Shen Z, Abou-Gharbia MA, Bach AC 3rd, Harrison BL, Kagan N, Kleintop T, Magolda R, Marathias V, Robichaud AJ, Sabb AL, Zhang MY, Andree TH, Aschmies SH, Beyer C, Comery TA, Day M, Grauer SM, Hughes ZA, Rosenzweig-Lipson S, Platt B, Pulicicchio C, Smith DE, Sukoff-Rizzo SJ, Sullivan KM, Adedoyin A, Huselton C, Hirst WD.

J Med Chem. 2010 May 27;53(10):4066-84. doi: 10.1021/jm1000908.

PMID:
20443629
16.

Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes.

Kelly MP, Logue SF, Brennan J, Day JP, Lakkaraju S, Jiang L, Zhong X, Tam M, Sukoff Rizzo SJ, Platt BJ, Dwyer JM, Neal S, Pulito VL, Agostino MJ, Grauer SM, Navarra RL, Kelley C, Comery TA, Murrills RJ, Houslay MD, Brandon NJ.

Proc Natl Acad Sci U S A. 2010 May 4;107(18):8457-62. doi: 10.1073/pnas.1000730107. Epub 2010 Apr 19.

17.

Social odor recognition: a novel behavioral model for cognitive dysfunction in Parkinson's disease.

Monaghan MM, Leddy L, Sung ML, Albinson K, Kubek K, Pangalos MN, Reinhart PH, Zaleska MM, Comery TA.

Neurodegener Dis. 2010;7(1-3):153-9. doi: 10.1159/000289227. Epub 2010 Mar 3.

PMID:
20197696
18.

5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.

Haydar SN, Yun H, Andrae PM, Mattes J, Zhang J, Kramer A, Smith DL, Huselton C, Graf R, Aschmies S, Schechter LE, Comery TA, Robichaud AJ.

J Med Chem. 2010 Mar 25;53(6):2521-7. doi: 10.1021/jm901674f.

PMID:
20170099
19.

Benzimidazole- and indole-substituted 1,3'-bipyrrolidine benzamides as histamine H3 receptor antagonists.

Cole DC, Gross JL, Comery TA, Aschmies S, Hirst WD, Kelley C, Kim JI, Kubek K, Ning X, Platt BJ, Robichaud AJ, Solvibile WR, Stock JR, Tawa G, Williams MJ, Ellingboe JW.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1237-40. doi: 10.1016/j.bmcl.2009.11.122. Epub 2009 Dec 4.

PMID:
20042333
20.

Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease.

Basi GS, Feinberg H, Oshidari F, Anderson J, Barbour R, Baker J, Comery TA, Diep L, Gill D, Johnson-Wood K, Goel A, Grantcharova K, Lee M, Li J, Partridge A, Griswold-Prenner I, Piot N, Walker D, Widom A, Pangalos MN, Seubert P, Jacobsen JS, Schenk D, Weis WI.

J Biol Chem. 2010 Jan 29;285(5):3417-27. doi: 10.1074/jbc.M109.045187. Epub 2009 Nov 18.

21.

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.

Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, Adkins K, Leach MW, Clarke DW, Huryn D, Abou-Gharbia M, Magolda R, Bard J, Frick G, Raje S, Forlow SB, Balliet C, Burczynski ME, Reinhart PH, Wan HI, Pangalos MN, Jacobsen JS.

J Pharmacol Exp Ther. 2009 Nov;331(2):598-608. doi: 10.1124/jpet.109.152975. Epub 2009 Aug 11.

PMID:
19671883
22.

Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.

Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ.

J Pharmacol Exp Ther. 2009 Nov;331(2):574-90. doi: 10.1124/jpet.109.155994. Epub 2009 Aug 6.

PMID:
19661377
23.

SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist.

Haydar SN, Ghiron C, Bettinetti L, Bothmann H, Comery TA, Dunlop J, La Rosa S, Micco I, Pollastrini M, Quinn J, Roncarati R, Scali C, Valacchi M, Varrone M, Zanaletti R.

Bioorg Med Chem. 2009 Jul 15;17(14):5247-58. doi: 10.1016/j.bmc.2009.05.040. Epub 2009 May 21. Erratum in: Bioorg Med Chem. 2010 Jan 15;18(2):985.

PMID:
19515567
24.

Identification of a novel series of 3-piperidinyl-5-sulfonylindazoles as potent 5-HT6 ligands.

Liu KG, Lo JR, Comery TA, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE, Robichaud AJ.

Bioorg Med Chem Lett. 2009 Jun 15;19(12):3214-6. doi: 10.1016/j.bmcl.2009.04.108. Epub 2009 May 3.

PMID:
19433358
25.

A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits.

Leiser SC, Bowlby MR, Comery TA, Dunlop J.

Pharmacol Ther. 2009 Jun;122(3):302-11. doi: 10.1016/j.pharmthera.2009.03.009. Epub 2009 Apr 5. Review.

PMID:
19351547
26.

1-Sulfonylindazoles as potent and selective 5-HT6 ligands.

Liu KG, Lo JR, Comery TA, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE, Robichaud AJ.

Bioorg Med Chem Lett. 2009 May 1;19(9):2413-5. doi: 10.1016/j.bmcl.2009.03.071. Epub 2009 Mar 21.

PMID:
19345582
27.

The supra-additive hyperactivity caused by an amphetamine-chlordiazepoxide mixture exhibits an inverted-U dose response: negative implications for the use of a model in screening for mood stabilizers.

Kelly MP, Logue SF, Dwyer JM, Beyer CE, Majchrowski H, Cai Z, Liu Z, Adedoyin A, Rosenzweig-Lipson S, Comery TA.

Pharmacol Biochem Behav. 2009 Jun;92(4):649-54. doi: 10.1016/j.pbb.2009.03.003. Epub 2009 Mar 18.

PMID:
19303035
28.

Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.

Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, Jow B, Kowal D, Gianfriddo M, Kelley C, Zanelli U, Ghiron C, Haydar S, Dunlop J, Terstappen GC.

J Pharmacol Exp Ther. 2009 May;329(2):459-68. doi: 10.1124/jpet.108.150094. Epub 2009 Feb 17.

PMID:
19223665
29.

Identification of a series of benzoxazoles as potent 5-HT6 ligands.

Liu KG, Lo JR, Comery TA, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE, Robichaud AJ.

Bioorg Med Chem Lett. 2009 Feb 15;19(4):1115-7. doi: 10.1016/j.bmcl.2008.12.107. Epub 2009 Jan 3.

PMID:
19152787
30.

WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.

Grauer SM, Graf R, Navarra R, Sung A, Logue SF, Stack G, Huselton C, Liu Z, Comery TA, Marquis KL, Rosenzweig-Lipson S.

Psychopharmacology (Berl). 2009 May;204(1):37-48. doi: 10.1007/s00213-008-1433-z. Epub 2008 Dec 20.

PMID:
19107466
31.

(S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor.

Cole DC, Stock JR, Kreft AF, Antane M, Aschmies SH, Atchison KP, Casebier DS, Comery TA, Diamantidis G, Ellingboe JW, Harrison BL, Hu Y, Jin M, Kubrak DM, Lu P, Mann CW, Martone RL, Moore WJ, Oganesian A, Riddell DR, Sonnenberg-Reines J, Sun SC, Wagner E, Wang Z, Woller KR, Xu Z, Zhou H, Jacobsen JS.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):926-9. doi: 10.1016/j.bmcl.2008.11.116. Epub 2008 Dec 6.

PMID:
19097890
32.

Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b']di pyrrole-1(2H)-carboxamide).

Dunlop J, Lock T, Jow B, Sitzia F, Grauer S, Jow F, Kramer A, Bowlby MR, Randall A, Kowal D, Gilbert A, Comery TA, Larocque J, Soloveva V, Brown J, Roncarati R.

J Pharmacol Exp Ther. 2009 Mar;328(3):766-76. doi: 10.1124/jpet.108.146514. Epub 2008 Dec 2.

PMID:
19050173
33.

Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease.

Mayer SC, Kreft AF, Harrison B, Abou-Gharbia M, Antane M, Aschmies S, Atchison K, Chlenov M, Cole DC, Comery T, Diamantidis G, Ellingboe J, Fan K, Galante R, Gonzales C, Ho DM, Hoke ME, Hu Y, Huryn D, Jain U, Jin M, Kremer K, Kubrak D, Lin M, Lu P, Magolda R, Martone R, Moore W, Oganesian A, Pangalos MN, Porte A, Reinhart P, Resnick L, Riddell DR, Sonnenberg-Reines J, Stock JR, Sun SC, Wagner E, Wang T, Woller K, Xu Z, Zaleska MM, Zeldis J, Zhang M, Zhou H, Jacobsen JS.

J Med Chem. 2008 Dec 11;51(23):7348-51. doi: 10.1021/jm801252w.

PMID:
19012391
34.

ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.

Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL.

J Pharmacol Exp Ther. 2008 Dec;327(3):827-39. doi: 10.1124/jpet.108.136580. Epub 2008 Aug 27.

PMID:
18753411
35.

A regiospecific synthesis of a series of 1-sulfonyl azepinoindoles as potent 5-HT6 ligands.

Liu KG, Lo JR, Comery TA, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE, Robichaud AJ.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):3929-31. doi: 10.1016/j.bmcl.2008.06.030. Epub 2008 Jun 13.

PMID:
18583130
36.

Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.

Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, Zhou H, Atchison K, Wagner E, Zaleska MM, Das I, Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Magolda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN.

Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8754-9. doi: 10.1073/pnas.0710823105. Epub 2008 Jun 16.

37.

ApoE promotes the proteolytic degradation of Abeta.

Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE.

Neuron. 2008 Jun 12;58(5):681-93. doi: 10.1016/j.neuron.2008.04.010.

38.

The 5-HT(2C) receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test.

Navarra R, Comery TA, Graf R, Rosenzweig-Lipson S, Day M.

Behav Brain Res. 2008 Apr 9;188(2):412-5. doi: 10.1016/j.bbr.2007.11.016. Epub 2007 Nov 29.

PMID:
18191235
39.

Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405).

Hirst WD, Andree TH, Aschmies S, Childers WE, Comery TA, Dawson LA, Day M, Feingold IB, Grauer SM, Harrison BL, Hughes ZA, Kao J, Kelly MG, van der Lee H, Rosenzweig-Lipson S, Saab AL, Smith DL, Sullivan K, Rizzo SJ, Tio C, Zhang MY, Schechter LE.

J Pharmacol Exp Ther. 2008 Apr;325(1):134-45. doi: 10.1124/jpet.107.133082. Epub 2008 Jan 8.

PMID:
18182558
40.

Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test.

Navarra R, Graf R, Huang Y, Logue S, Comery T, Hughes Z, Day M.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):34-41. Epub 2007 Jun 27.

PMID:
17714843
41.

The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease.

Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS.

Mol Cell Neurosci. 2007 Apr;34(4):621-8. Epub 2007 Jan 25.

PMID:
17336088
42.

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.

Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S.

J Pharmacol Exp Ther. 2007 Jan;320(1):486-96. Epub 2006 Oct 12.

PMID:
17038512
43.

Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease.

Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH, Bloom FE.

Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5161-6. Epub 2006 Mar 20.

44.

Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease.

Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL.

J Neurosci. 2005 Sep 28;25(39):8898-902.

45.

Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits.

Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA, Weiler IJ, Greenough WT.

Proc Natl Acad Sci U S A. 1997 May 13;94(10):5401-4.

46.

Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation.

Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, Miyashiro K, Comery TA, Patel B, Eberwine J, Greenough WT.

Proc Natl Acad Sci U S A. 1997 May 13;94(10):5395-400.

47.

Increased density of multiple-head dendritic spines on medium-sized spiny neurons of the striatum in rats reared in a complex environment.

Comery TA, Stamoudis CX, Irwin SA, Greenough WT.

Neurobiol Learn Mem. 1996 Sep;66(2):93-6.

PMID:
8946401
48.

Synaptogenesis and Fos expression in the motor cortex of the adult rat after motor skill learning.

Kleim JA, Lussnig E, Schwarz ER, Comery TA, Greenough WT.

J Neurosci. 1996 Jul 15;16(14):4529-35.

49.

Expression of DMAP-45R in the rat visual cortex is modulated by visual experience.

Werner D, Hawrylak N, Comery TA, Karr TL, Greenough WT.

Brain Res. 1995 Dec 1;701(1-2):55-60.

PMID:
8925299

Supplemental Content

Loading ...
Support Center